Significant reduction in insoluble aggregates, decrease in muscle fibrosis, and normalization of muscle strength was seen in an OPMD mouse model after AAV-PABPN1 administration [240]. Here, PABPN1 is linked to oculopharyngeal muscular dystrophy.